Sort
1,049,261 grants matching “t cell”
Leadership Group for a Global HIV Vaccine Clinical Trials Network
$11,269,896Lawrence Corey · Fred Hutchinson Cancer Research Center · UM1 · FY2013 · AI
Inner City Asthma consortium 3 (ICAC3)
$11,206,205Daniel J Jackson · University Of Wisconsin-Madison · UM1 · FY2019 · AI
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
$11,203,040James Dale Berry · Massachusetts General Hospital · U01 · FY2023 · NS
Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).
$11,192,232Jinsy Andrews · Columbia University Health Sciences · U01 · FY2023 · NS
Type 1 Diabetes Trialnet: Operations Coord. Center
$11,185,161John M Lachin · George Washington University · U01 · FY2007 · DK
Infectious Diseases Research Technologies Core - Bethesda
$11,169,663Robert Hohman · National Institute Of Allergy And Infectious Diseases · ZIC · FY2013 · AI
NIMH Center for Collaborative Genetic Studies
$11,104,886Jay Arnold Tischfield · Rutgers, The State Univ Of N.J. · U24 · FY2012 · MH
Adult Changes in Thought (ACT) Research Program
$11,060,502Linda Kathleen McEvoy · Kaiser Foundation Research Institute · U19 · FY2023 · AG
Adult Changes in Thought (ACT) Research Program
$11,040,953Linda Kathleen McEvoy · Kaiser Foundation Research Institute · U19 · FY2024 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$11,038,947Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2023 · AG
Cancer and Leukemia Group B
$11,034,745Monica M Bertagnolli · Brigham And Women'S Hospital · U10 · FY2010 · CA
Consortia for Innovative AIDS Research in Nonhuman Primates
$11,020,286Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2017 · AI
California National Primate Research Center
$11,016,202Cameron S. Carter · University Of California At Davis · P51 · FY2016 · OD
Support of collaborative research initiatives
$11,012,140David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2020 · CA
Translational Cancer Immune Monitoring and Analysis Center (TCIMAC)
$11,005,230Ignacio I. Wistuba · University Of Tx Md Anderson Can Ctr · U24 · FY2017 · CA
Research Services Core (RSC)
$10,999,069Samuel Michael · National Center For Advancing Translational Sciences · ZIC · FY2021 · TR
Integrative Single-Cell Atlas of Host and Microenvironment in Colorectal Neoplastic Transformation
$10,993,061Robert J Coffey · Vanderbilt University Medical Center · U2C · FY2018 · CA
Cancer Center Support Grant (Comprehensive)
$10,977,925Leland H Hartwell · Fred Hutchinson Cancer Research Center · P30 · FY2009 · CA
CRTP CCR Dedicated Cores
$10,969,625Mariam Malik · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA
BMT Clinical Research Network Data Coordinating Center
$10,957,493Mary M Horowitz · Medical College Of Wisconsin · U01 · FY2007 · HL
REGIONAL PRIMATE RESEARCH CENTER
$10,950,971Oregon Health And Science University · P51 · FY2003 · RR
SDMC: HIV Vaccine Trials Network
$10,940,011Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2016 · AI
Clinical Core
$10,927,979Ziad Nahas · University Of Minnesota · U54 · FY2024 · AT
CONSIDERING THE HIGH SPONTANEOUS INCIDENCE OF GASTROINTESTINAL (GI) CANCER AND HIGHER INCIDENCE OF PREMALIGNANT COLONIC POLYPS AN EVEN MODEST INCREASE BY SPACE RADIATION EXPOSURE COULD HAVE A SIGNIFICANT EFFECT ON ASTRONAUTS HEALTH RISK ESTIMATES DURING AND AFTER LONG-DURATION MANNED SPACE FLIGHTS. HOWEVER THERE IS SUBSTANTIAL UNCERTAINTY FOR GI CANCER RISK ESTIMATION FROM SPACE RADIATION DUE TO THE LACK OF IN VIVO HUMAN DATA. THIS PROPOSAL ADDRESSES THE CATEGORY IN THE CURRENT SOLICITATION INVOLVING `NEW APPROACHES TOWARDS `MECHANISTIC UNDERSTANDING OF GI CANCER RISK USING `NEW BIOLOGICAL MODELS FOR `STUDIES OF RADIATION QUALITY AND DOSE-RATE EFFECTS IN RELATION TO `INDIVIDUAL RADIATION SENSITIVITY . THE OVERARCHING GOAL OF THE CURRENT PROPOSAL IS TO SPECIFICALLY INVESTIGATE CELLULAR AND MOLECULAR HYPOTHESIS DRIVEN MECHANISMS IN RELEVANT MOUSE MODELS THAT WILL CONTRIBUTE TO CARCINOGENIC RISK ESTIMATES OF GI CANCER AFTER EXPOSURE TO SPACE RADIATION BEAMS PRIORITIZED IN THE CURRENT SOLICITATION. WE HAVE CHOSEN HIGH PRIORITY HZE BEAMS. SINCE MAXIMAL EFFECTS HAVE ALREADY BEEN SEEN WITH 28SI IONS THIS WILL BE A PRIORITY AND WE WILL EXTEND TO LOWER Z AT SIMILAR ENERGY USING 16O AND 4HE IONS. HAVING FOUND MODEST EFFECTS IN SOME STUDIES WITH PROTONS AND CONSIDERING THE IMPORTANCE OF ASSESSING THE EFFECTS OF MIXED BEAMS WE WILL TAKE ADVANTAGE OF THE AVAILABILITY OF THE SEQUENTIAL FIELD PROTON/56FE (0.2/150 KEV/M) BEAM TO START TO REPRESENT THE MIXED PARTICLE RADIATION IN SPACE. WE WILL CONSULT WITH NASA ON BEAM PRIORITIZATION AND CONSIDER THE GCR SIMULATOR AS THE STUDY PROGRESSES. SPECIFICALLY THIS PROPOSAL SEEKS TO DETERMINE INCIDENCE AND GRADE AS WELL AS IDENTIFY MOLECULAR PERTURBATIONS AND TARGET CELLS ASSOCIATED WITH INTESTINAL AND GASTRIC (STOMACH) TUMORS THROUGH MONITORING OF CHANGES IN THE TUMOR NUMBER HISTOLOGY GENE EXPRESSION METABOLOME AND IN THE GENOME OF THE PROPOSED MODEL SYSTEM AFTER EXPOSURE TO THESE SPACE-RADIATION BEAMS. WE ARE PROPOSING FOUR COMPLEMENTARY AIMS (AND PROJECTS) THAT WILL HAVE A COMMON OBJECTIVE TO DEVELOP A MORE RELIABLE GI CANCER RISK PREDICTION MODEL. 1] QUANTITATIVELY ASSESS GI TUMORIGENESIS IN MOUSE MODELS OF GI CANCER AND COLLECT SAMPLES FOR QUALITATIVE ANALYSIS (PROJECT 1) 2] DISSECTION OF THE SIGNALING EVENTS AND CONSEQUENCES IN GASTROINTESTINAL CELLS OF THE PERSISTENT EFFECTS OF SPACE RADIATION (PROJECT 2) 3] CHARACTERIZATION OF RADIATION-INDUCED NEOPLASTIC EVENTS IN NORMAL DIPLOID HUMAN COLONOCYTES (PROJECT 3) 4] DEVELOPMENT OF SYSTEMS BIOLOGY (PROJECT 4A) AND MATHEMATICAL MODELING (PROJECT 4B) APPROACHES FOR GI CANCER RISK ASSESSMENT.
$10,926,096Georgetown University · · FY2015 · National Aeronautics and Space Administration
DISTRIBUTED CELL-FREE MANUFACTURING OF BIOLOGICS-BASED MEDICAL COUNTERMEASURES
$10,923,276Northwestern University · · FY2023 · Department of the Army